Today: 20 May 2026
Camtek stock jumps to a new high after Needham lifts target — what traders watch next
6 January 2026
1 min read

Camtek stock jumps to a new high after Needham lifts target — what traders watch next

New York, Jan 6, 2026, 13:26 EST — Regular session

  • Camtek shares jump about 7.5% and touch an intraday high near $134.80
  • Needham raises its price target to $135, pointing to momentum in HBM-linked demand
  • Investors look ahead to U.S. jobs data on Jan. 9 and Camtek’s next earnings update

Camtek Ltd shares jumped 7.5% to $133.18 in afternoon trade on Tuesday, pushing the chip inspection equipment maker to a fresh high. Needham raised its price target to $135 from $125, according to a summary of analyst actions.

The move comes as chip-related stocks climb broadly, extending a Wall Street rally that has leaned on technology names. Investors are also bracing for December nonfarm payrolls data on Friday, a key gauge of U.S. job growth that can shift interest-rate bets.

Needham analyst Charles Shi wrote that high-bandwidth memory, or HBM — stacked memory used in AI accelerators — is moving beyond simple stacking, helping sustain demand. He urged investors to “look for names in this space that has been forgotten for a while,” saying back-end tools used in packaging and testing may outperform front-end wafer-fab gear in 2026. TipRanks

Camtek’s gains outpaced the iShares Semiconductor ETF, up about 2.8%, and the VanEck Semiconductor ETF, up about 2.5%. Shares of peers Onto Innovation and KLA were up about 4.6% and 3.4%, while Nova rose about 1.3%.

Camtek sells inspection and metrology systems — tools that measure chip features and flag defects — used from wafer production through early-stage assembly. In November, the company forecast fourth-quarter revenue of about $127 million and CEO Rafi Amit cited “increasing demand for high-performance computing for AI applications.” Camtek

The rally has carried the stock above its prior 52-week high of $129.41 and well above its 50-day moving average near $110.78, a trend marker based on recent closing prices.

But the move also raises the bar for the next set of results and guidance. Any sign that packaging-related spending is cooling — or that customers are delaying tool deliveries — could hit orders quickly, especially if a rebound in bond yields weighs on high-multiple chip names.

Stock Market Today

  • Williams-Sonoma Gains 1.58% as Market Declines, Eyes Upcoming Earnings
    May 19, 2026, 7:31 PM EDT. Williams-Sonoma (WSM) shares rose 1.58% to $171.83, outperforming the S&P 500's 0.67% drop. The stock had declined 16.27% over the past month, lagging the sector's 0.69% loss but behind the S&P 500's 4% gain. Investors await WSM's upcoming earnings report, expected to show $1.80 per share in EPS, down 2.7% year-over-year, with revenue projected to rise 4.25% to $1.8 billion. The company's full-year estimates anticipate 4.75% EPS growth and 4.39% revenue growth. Analyst estimate revisions have nudged EPS projections higher by 0.58% in 30 days, with WSM holding a Zacks Rank #3 (Hold). Valuation indicators show a Forward P/E of 18.27, slightly below industry average, while the PEG ratio of 2.12 exceeds the Retail - Home Furnishings sector average of 1.63.

Latest articles

James Hardie Drops After Warning on Housing, Even With Q4 Beat

James Hardie Drops After Warning on Housing, Even With Q4 Beat

20 May 2026
James Hardie’s U.S.-listed shares dropped 6.1% Tuesday and slid another 2.6% after hours after reporting a 35% fall in quarterly net income to $28.5 million, despite a 45% jump in net sales to $1.40 billion. The company cited weak housing demand and warned the market remains uncertain. ASX shares had not traded post-earnings; they last closed at A$26.78, up 2.9%.
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

20 May 2026
SELLAS Life Sciences shares rose 4.1% to $7.59 Tuesday after CEO Angelos Stergiou said its Phase 3 AML trial is two events from final analysis. The company reported $107.1 million in cash and a first-quarter net loss of $8.4 million. The REGAL trial’s main measure is overall survival. SELLAS remains blinded to results until the 80th event triggers data review.
Red Robin Shares Rise After Earnings Beat

Red Robin Shares Rise After Earnings Beat

20 May 2026
Red Robin shares surged 15.6% after hours to $4.45 Tuesday, following first-quarter revenue of $378.3 million that beat Wall Street estimates despite a 0.6% drop in comparable sales and a 1.6% decline in guest traffic. Net loss was $2.2 million, or 12 cents per share. The company reaffirmed its 2026 outlook and said refranchising talks are in final stages.
Boeing stock rises as Bernstein lifts target to $277, but 737 supply signals stay in focus
Previous Story

Boeing stock rises as Bernstein lifts target to $277, but 737 supply signals stay in focus

Dow Jones today: Record highs hold as investors brace for Friday jobs report
Next Story

Dow Jones today: Record highs hold as investors brace for Friday jobs report

Go toTop